肿瘤新抗原mRNA疫苗在加速审批的背景下，肿瘤突变抗原的研究价值越来越大，为此，我们通过文献挖掘，为读者整理了各种肿瘤的已验证肿瘤突变抗原清单，我们将陆续发布。以下是目前公布的胃癌肿瘤抗原肽清单，该清单均支持定制生产 (定制咨询请扫描本页右侧联系人二维码)。可定制生产：
- 检测或分选抗原特异性T细胞的流式试剂、磁珠分选试剂
- 构建抗原肽和MHC复合物，用于合成人工呈递物，从而刺激T细胞增殖
乳腺癌抗原蛋白的抗原肽数量分布
| 抗原蛋白 | 抗原肽 | 呈递抗原的MHC | 验证论文 |
|---|---|---|---|
| Mammaglobin-A | LIYDSSLCDL | HLA-A2 | Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004 |
| Mammaglobin-A | KLLMVLMLA | HLA-A2 | Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004 |
| Mammaglobin-A | LMVLMLAAL | HLA-A2 | Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004 |
| Mammaglobin-A | FLNQTDETL | HLA-A2 | Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004 |
| Mammaglobin-A | TINPQVSKT | HLA-A2 | Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004 |
| Cellular tumor antigen p53 | RMPEAAPPV | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | LLGRNSFEV | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | GLAPPQHLIRV | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | SLPPPGTRV | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | KLCPVQLWV | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | YLGSYGFRL | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | STPPPGATRV | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | KTCPVQLWV | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Cellular tumor antigen p53 | YQGSYGFRL | HLA-A2 | Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004 |
| Heat shock 70 kDa protein 1 | LLLLDVAPL | HLA-A*02:01 | Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer 2004 |
| Heat shock 70 kDa protein 1 | LLDVAPLSL | HLA-A*02:01 | Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer 2004 |
| SMN interacting protein 1-delta; gemin-2; component of gems 2; survival of motor neuron protein interacting protein 1; gem-associated protein 2; gem (nuclear organelle) associated protein 2 | AQCPDVLV | HLA-A*02:06 | Neoantigens elicit T cell responses in breast cancer. Sci Rep 2021 |
| PARP10 protein | SISCHVFCL | HLA-A*02:06 | Neoantigens elicit T cell responses in breast cancer. Sci Rep 2021 |
| PNMA-like protein 1, PNMA8A, PNMAL1 | RTQDAEFLK | HLA-A*11:01 | Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. J Immunother Cancer 2021 |
| pleckstrin homology domain containing, family E (with leucine rich repeats) member 1, suprachiasmatic nucleus circadian oscillatory protein, SCN circadian oscillatory protein, PH domain-containing family E member 1 | KLKAIPTTL | HLA-A*02:01 | Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine. Front Oncol 2022 |
| VILL | QLQKANVLL | HLA-A*02:01 | Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine. Front Oncol 2022 |
| tumor necrosis factor receptor superfamily, member 6; APO-1 cell surface antigen; apoptosis antigen 1; Fas AMA; CD95 antigen; FASLG receptor; apoptosis-mediating surface antigen FAS; apoptosis signaling receptor FAS; Fas (TNF receptor superfamily, member 6); TNF receptor superfamily member 6; mutant tumor necrosis receptor superfamily member 6 | VARLSSKSV | HLA-C*03:04 | Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine. Front Oncol 2022 |
| Integrin beta-8 | ALMEQQHYV | HLA-A*02:01 | First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012 |
| Disintegrin and metalloproteinase domain-containing protein 17 | YLIELIDRV | HLA-A*02:01 | First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012 |
| Epithelial discoidin domain-containing receptor 1 | FLAEDALNTV | HLA-A*02:01 | First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med 2012 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha, Phosphoinositide 3-kinase alpha, Phosphoinositide-3-kinase catalytic alpha polypeptide, Serine/threonine protein kinase PIK3CA, PIK3CA | ALHGGWTTK | HLA-A*03:01 | Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med 2022 |
| Lactadherin | GLQHWVPEL | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| TCRgamma alternate reading frame protein | FLRNFSLML | HLA-A*02:01 | Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004 |
| TCRgamma alternate reading frame protein | FVFLRNFSL | HLA-A*02:01 | Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004 |
| TCRg | FLANFSLML | HLA-A*02:01 | Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004 |
| TCRg | FLRNFSLMV | HLA-A*02:01 | Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004 |
| Lactadherin | NLLRRMWVT | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Lactadherin | NLFETPVEA | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Prostate-specific antigen | FLTPKKLQCV | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Cellular tumor antigen p53 | STPPPGTRV | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Carcinoembryonic antigen-related cell adhesion molecule 5 | GVLVGVALI | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| G1/S-specific cyclin-D1 | LLGATCMFV | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Melanoma-associated antigen 2 | KMVELVHFL | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Heparanase | DLIFGLNAL | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Apoptosis regulator Bcl-2 | KTLLSLALV | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Mucin-1 | LLLLTVLTV | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Receptor tyrosine-protein kinase erbB-2 | KIFGSLAFL | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Heparanase | LLLGPLGPL | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Heparanase | ALPPPLMLL | HLA-A*02:01 | The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006 |
| Arginase-1 | AKDIVYIGLRDVDPGEHYIL | HLA class I | Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial. Front Immunol 2022 |
| Arginase-1 | DVDPGEHYILKTLGIKYFSM | HLA class I | Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial. Front Immunol 2022 |
乳腺癌抗原清单使用方法：
肿瘤微环境研究：检测肿瘤浸润淋巴细胞中，肿瘤抗原特异性淋巴细胞的数量实现。具体方式是：根据清单内容，将抗原肽和HLA合成为抗原肽MHC复合物荧光四聚体，通过流式细胞检测方法，检测肿瘤浸润淋巴细胞的含量。
肿瘤免疫细胞的全身分布：
通过检测外周血中肿瘤抗原特异性淋巴细胞的数量实现。具体方法同上。
过继性肿瘤免疫细胞治疗：
使用清单中抗原肽，刺激淋巴细胞，而后使用抗原肽MHC复合物荧光四聚体或磁珠四聚体，通过流式分选或磁珠分选细胞，经体外细胞增殖后，回输体内，评估肿瘤抑制效果。
肿瘤抗原特异性TCR测序：
通过肿瘤浸润淋巴细胞、或外周血淋巴细胞，通过分选后进行单细胞TCR测序，获得抗原特异性T细胞的TCR序列，进一步进行TCR-T疗法研究。
肿瘤疫苗片段筛选：
综合上述过程，获得具有激活T细胞杀伤肿瘤细胞的经验证抗原肽MHC复合物，用于肿瘤疫苗构建。
